EUCTR2015-002739-17-ES进行中（未招募）1 期
A Phase 3, Randomized, Open-Label, Assessor-Blind, Non-Inferiority, Active Comparator Study Evaluating the Efficacy and Safety of Liprotamase in Subjects with Cystic Fibrosis-Related Exocrine Pancreatic Insufficiency - SOLUTION Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine Origin
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 入组人数
- 150
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- All
入选标准
- •1.Cystic Fibrosis based on the disease diagnostic criteria:
- •?Two clinical features consistent with CF, and
- •a.genotype with 2 identifiable mutations consistent with CF, or
- •b.sweat chloride >60 mEq/L by quantitative pilocarpine iontophoresis.
- •2.Males or females ? 7 years of age at the time of screening.
- •3.Have fecal elastase <100 mcg/g stool measured during screening unless previously documented.
- •4.Have CFA during screening of ?80% while receiving PERT therapy.
- •5.Are clinically stable with no evidence of acute upper or lower respiratory tract infection in the last 10 days prior to screening.
- •6.Are of fair or better nutritional status as defined by:
- •?BMI ?16.0 kg/m2 for female subjects ?20 years of age, or
- •?BMI ?16.5 kg/m2 for male subjects ?20 years of age, or
- •?BMI ?25th percentile for subjects 7 to <20 years of age.
- •?Weight for all age groups has remained stable (no more than a 5% decline) during the 90 days prior to screening.
- •7.Are able to take pancreatic enzyme supplementation in the form of capsules.
- •8.Have been using the same pancreatic enzyme treatment for the past 30 days without change in dosing regimen.
- •9.Are able to perform testing and procedures required for the study, as judged by the Investigator.
- •10.If adult, have given written informed consent or assent as required by Anthera or its designee and the Institutional Review Board/Independent Ethic Committee (IRB/IEC). If not adult, have parent or legal guardian who has given written informed consent approved by Anthera or its designee and the IRB/IEC governing the site.
- •Are the trial subjects under 18? yes
- •Number of subjects for this age range: 75
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 75
- •F.1.3 Elderly (>=65 years) no
- •F.1.3.1 Number of subjects for this age range
排除标准
- •1.Presently using Pancreaze as enzyme preparation for treatment of EPI. Patients are not required to be Pancreaze naïve but should not have received Pancreaze within 30 days of screening.
- •2.Women who are breast-feeding during the study.
- •3.A history or diagnosis of fibrosing colonopathy (FC).
- •4.History of distal intestinal obstruction syndrome (DIOS) in the 6 months prior to the screening visit.
- •5.Any chronic diarrheal illness unrelated to pancreatic insufficiency (eg, infectious gastroenteritis, lactose intolerance, sprue or inflammatory bowel disease).
- •6.A history of liver transplant, lung transplant, or significant surgical resection of the bowel. Significant resection of the bowel is defined as any resection of the terminal ileum or ileocecal valve. Patients who have had qualitative, long term changes in nutritional status after any other bowel resection (e.g., increased or new need for pancreatic enzyme supplementation compared to pre operative status in order to maintain the same nutritional status) should also be excluded.
- •7.Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) level ?5 times upper limit of normal (ULN), or total bilirubin level ?1.5 times ULN at the screening visit.
- •8.Signs and/or symptoms of liver cirrhosis or portal hypertension (eg, splenomegaly, ascites, esophageal varices), or documented liver disease unrelated to CF.
- •9.Forced expiratory volume in 1 second (FEV1) <30% of the predicted value.
- •10.Known hypersensitivity to food additives or Pancreaze.
- •11.Use of an enzyme preparation in excess of 10,000 lipase units/kg/day at screening or 2500 lipase units/kg per meal.
- •12.Uncontrolled hyperglycemia or uncontrolled CF-related diabetes.
- •13.Uncontrolled hyperuricemia or hyperuricosuria as determined by the principal Investigator (PI).
- •14.Feeding via an enteral tube.
- •15.Routine use of anti-diarrheals, anti-spasmodics, or cathartic laxatives, or a change in chronic osmotic laxative (eg, polyethylene glycol) regimen in the previous 3 months.
- •16.Any condition that the Investigator believes would interfere with the intent of this study or would make participation not in the best interests of the patient.
- •17.Unlikely to complete the study, as determined by the Investigator.
- •18.Currently enrolled in, or have discontinued within the last 30 days (prior to the screening visit) from a clinical trial involving use of an investigational drug, biologic or device, or are currently enrolled in any other type of medical research judged not to be scientifically or medically compatible with this study.
- •19.Females who are nursing, pregnant, intending to become pregnant or intending to nurse during the time of the study, or who have a positive pregnancy test at baseline. All sexually-active subjects of reproductive potential are required to use a reliable method of birth control. Females and males are required to use or start using a reliable method of birth control at least 2 weeks prior to randomization, throughout the study, and for at least 3 months following completion of study therapy. A reliable method of birth control is defined as one of the following: oral or injectable contraceptives, intrauterine device, contraceptive implants, tubal ligation, hysterectomy, or a double-barrier method (diaphragm with spermicidal foam or jelly, or a condom), abstinence or vasectomy.
研究者
相似试验
进行中（未招募）
1 期
Study of Oral Liprotamase Therapy Of Non-Porcine OrigiEUCTR2017-000571-85-ESANTHERA Pharmaceuticals, Inc.150
进行中（未招募）
1 期
Study of Oral Liprotamase Therapy Of Non-Porcine OrigiPancreatic Exocrine Insufficiency due to Cystic FibrosisEUCTR2017-000571-85-HUANTHERA Pharmaceuticals, Inc.192
进行中（未招募）
1 期
Study of Oral Liprotamase Therapy Of Non-Porcine OrigiEUCTR2017-000571-85-GBANTHERA Pharmaceuticals, Inc.150
进行中（未招募）
1 期
Study of Oral Liprotamase Unit-Matched Therapy Of Non-Porcine OrigiPancreatic exocrine Insufficiency due to Cystic FibrosisEUCTR2015-002739-17-HUANTHERA Pharmaceuticals, Inc.150
进行中（未招募）
1 期
Study of Oral Liprotamase Therapy Of Non-Porcine OrigiPancreatic Exocrine Insufficiency due to Cystic FibrosisEUCTR2017-000571-85-PLANTHERA Pharmaceuticals, Inc.192